CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 51 - 60 of 730
Study Number Lead Group Study Title CIRB Study Status
A191402CD Alliance Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men Cancer Prevention and Control CIRB Available to Open
10129 ETCTN A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors Adult CIRB - Early Phase Emphasis Available to Open
AREN1721 COG A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups Pediatric CIRB Available to Open
AALL03N1 COG Understanding the Ethnic and Racial Differences in Survival in Children with Acute Lymphoblastic Leukemia Pediatric CIRB Available to Open
7977 ETCTN A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients with Advanced Solid Tumors Adult CIRB - Early Phase Emphasis Available to Open
10010 ETCTN A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination with Bevacizumab in Patients with Recurrent; Persistent or Metastatic Cervical Cancer Adult CIRB - Early Phase Emphasis Available to Open
AOST1322 COG A Phase II Study of Eribulin (IND# 122686; NSC# 707389) in Recurrent or Refractory Osteosarcoma: An Intergroup NCTN Phase II Study Pediatric CIRB Available to Open
E1505 ECOG A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (>= 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC) Adult CIRB - Late Phase Emphasis Available to Open
S1404 SWOG A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma Adult CIRB - Late Phase Emphasis Available to Open
CALGB-40601 CALGB Randomized Phase III Trial of Paclitaxel + Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer Adult CIRB - Late Phase Emphasis Available to Open
Displaying 51 - 60 of 730